COMPASS Pathways Sees Unusually High Options Volume (NASDAQ:CMPS)

COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) saw unusually large options trading activity on Friday. Stock traders bought 7,423 call options on the company. This represents an increase of 152% compared to the typical daily volume of 2,940 call options.

Analyst Ratings Changes

A number of research analysts recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of COMPASS Pathways in a research note on Wednesday. Morgan Stanley upped their price target on shares of COMPASS Pathways from $10.00 to $11.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. BTIG Research boosted their target price on shares of COMPASS Pathways from $7.00 to $14.00 and gave the company a “buy” rating in a research note on Monday, October 13th. Finally, Royal Bank Of Canada raised their target price on COMPASS Pathways from $16.00 to $21.00 and gave the stock an “outperform” rating in a research report on Friday. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.25.

COMPASS Pathways Stock Up 3.8%

NASDAQ CMPS traded up $0.27 during trading on Friday, reaching $7.40. The company’s stock had a trading volume of 1,115,718 shares, compared to its average volume of 1,547,970. COMPASS Pathways has a 1-year low of $2.25 and a 1-year high of $8.20. The stock has a market capitalization of $710.36 million, a PE ratio of -2.72 and a beta of 1.92. The company has a current ratio of 1.23, a quick ratio of 1.23 and a debt-to-equity ratio of 0.55. The business has a 50-day moving average price of $6.38 and a 200-day moving average price of $5.55.

COMPASS Pathways (NASDAQ:CMPS) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.38) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.02. On average, research analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Investors Weigh In On COMPASS Pathways

Several hedge funds have recently made changes to their positions in the stock. Advisory Services Network LLC acquired a new position in COMPASS Pathways in the third quarter worth $41,000. China Universal Asset Management Co. Ltd. increased its stake in shares of COMPASS Pathways by 46.7% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 18,272 shares of the company’s stock valued at $51,000 after buying an additional 5,817 shares during the period. BIT Capital GmbH acquired a new stake in shares of COMPASS Pathways during the 3rd quarter worth approximately $54,000. Conservest Capital Advisors Inc. boosted its position in shares of COMPASS Pathways by 32.5% in the 2nd quarter. Conservest Capital Advisors Inc. now owns 20,363 shares of the company’s stock worth $57,000 after purchasing an additional 5,000 shares during the last quarter. Finally, Northeast Financial Consultants Inc bought a new stake in COMPASS Pathways in the second quarter valued at about $59,000. Institutional investors own 46.19% of the company’s stock.

COMPASS Pathways Company Profile

COMPASS Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, COMPASS Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.